SCHEMBL18320448

SCHEMBL18320448

F[B-](F)(F)F.c1ccc(C[n+]2cccc3ccccc32)cc1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 13/20 0.67
BCHE P06276 11/20 0.67
KDM4E B2RXH2 1/20 0.57
NPC1 O15118 1/20 0.57
MITF O75030 1/20 0.57
ALDH1A1 P00352 1/20 0.57
GLA P06280 1/20 0.57
GAA P10253 1/20 0.57
HPGD P15428 1/20 0.57
HTT P42858 1/20 0.57
RAB9A P51151 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
MEN1 O00255 1/20 0.55
POLB P06746 1/20 0.55
APOBEC3A P31941 1/20 0.55
KMT2A Q03164 1/20 0.55
APOBEC3G Q9HC16 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29729955 0.93 ACHE (0.76) ACHEBCHEKDM4ENPC1MITF
SCHEMBL1127587 0.93 ACHE (0.76) ACHEBCHEKDM4ENPC1MITF
Bromide SCHEMBL1069897 0.91 ACHE (0.79) ACHEBCHEKDM4ENPC1MITF
Hydrochloric Acid SCHEMBL1071121 0.91 ACHE (0.73) ACHEBCHEKDM4ENPC1MITF
Hydrochloric Acid SCHEMBL29943765 0.91 ACHE (0.73) ACHEBCHEKDM4ENPC1MITF
SCHEMBL20263107 0.89 ACHE (0.67) ACHEBCHEKDM4ENPC1MITF
SCHEMBL20657095 0.89 ACHE (0.67) ACHEBCHEKDM4ENPC1MITF
SCHEMBL27540774 0.88 ACHE (0.65) ACHEBCHEKDM4ENPC1MITF
SCHEMBL9644491 0.86 ACHE (0.63) ACHEBCHEKDM4ENPC1MITF
SCHEMBL7026594 0.84 ACHE (0.56) ACHEBCHEKDM4ENPC1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2022-03-29 US claimed
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2021-05-20 US claimed
US-11926727-B2 Epoxy resin composition HUNTSMAN INTERNATIONAL LLC (US) 2024-03-12 US disclosed
US-20220135766-A1 Epoxy Resin Composition HUNTSMAN INTERNATIONAL LLC 2022-05-05 US disclosed
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2022-03-29 US disclosed
EP-3310838-B1 EPOXY RESIN COMPOSITION HUNTSMAN ADV MAT LICENSING SWITZERLAND GMBH (CH) 2021-08-18 EP disclosed
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2021-05-20 US disclosed
US-20180171101-A1 Epoxy Resin Composition HUNTSMAN INTERNATIONAL LLC 2018-06-21 US disclosed
EP-3310838-A1 EPOXY RESIN COMPOSITION Huntsman Advanced Materials Licensing (Switzerland) GmbH (CH) 2018-04-25 EP disclosed
WO-2016202608-A1 EPOXY RESIN COMPOSITION HUNTSMAN ADVANCED MATERIALS (SWITZERLAND) GMBH (CH) 2016-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same CBR1, POR, CAT ACHE 941/4885BCHE 1349/4885KDM4E 3025/4885
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME CBR1, POR, CAT ACHE 1023/4885BCHE 1674/4885KDM4E 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.